Top Markets
#1 Merlin's Seal BTC Merlin's Seal BTC +42.01%
#2 0G 0G +31.99%
#3 Fake World Assets Fake World Assets +21.86%
#4 Zora Zora +18.19%
#5 Full Moon Full Moon +17.70%
#6 SAFEcoin SAFEcoin +17.57%
#7 Nockchain Nockchain +15.63%
#8 ADO Protocol ADO Protocol +15.62%
#9 Axelar Axelar +13.79%
#10 Notcoin Notcoin +12.84%
Coin of the day
Merlin's Seal BTC Merlin's Seal BTC
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
Graphite Bio, Inc. Graphite Bio, Inc.

Graphite Bio, Inc.

GRPH
Classificação em ações #12751
Graphite Bio, Inc. is a clinical-stage gene editing company dedicated to... Graphite Bio, Inc. is a clinical-stage gene editing company dedicated to developing innovative therapeutic solutions for severe and life-threatening illnesses across the United States. Its primary investigational therapy, GPH101, is an autologous, gene-edited hematopoietic stem cell product specifically engineered to directly correct the underlying mutation causing sickle cell disease, thereby restoring normal adult hemoglobin production. The company's pipeline also features GPH201, intended for the treatment of X-linked severe combined immunodeficiency syndrome, and GPH301, an experimental candidate designed to address Gaucher disease, a genetic disorder characterized by a deficiency in the glucocerebrosidase enzyme. Initially established as Integral Medicines, Inc., the company rebranded to Graphite Bio, Inc. in August 2020. Founded in 2017, Graphite Bio's operations are based out of its headquarters in South San Francisco, California.
Preço da ação
$22.26
Última sincronização: 2024-03-22
Valor de mercado
$553.40M
Variação (1 dia)
0.00%
Variação (1 ano)
0.00%
País
US
Negociar Graphite Bio, Inc. (GRPH)

Categoria

Healthcare
Receita da Graphite Bio, Inc. (GRPH)
Receita em Aug 2026 TTM: 0
De acordo com os últimos relatórios financeiros da Graphite Bio, Inc., a receita atual da empresa (TTM) é 0. Em 2026, a empresa obteve uma receita de 0 igual a a receita do ano 2026, que foi de 0. A receita é o valor total gerado pela venda de bens ou serviços. Ao contrário do lucro, nenhuma despesa é subtraída.
Histórico de receita da Graphite Bio, Inc. de 2026 a 2026
Receita no final de cada ano
Ano Receita Alterar
Não há dados suficientes para as datas fornecidas.
Receita de empresas similares ou concorrentes
Empresa Receita Diferença de Receita País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH